Assessment of Effect of Atenolol and Enalapril on Trace Elements in Pre and Postmenopausal Women with Essential Hypertension
Background: Studies conducted in recent times have reported the involvement of trace elements in the pathogenesis of certain cardiovascular diseases particularly hypertension. So, the present study was planned to evaluate the influence of the antihypertensive drugs enalapril and atenolol on blood pressure and serum concentration of zinc, magnesium, lead, aluminum and vanadium. Methods: For the study, selection of 30 pre and 30 post-menopausal women patients with mild to moderate essential hypertension and 60 normal controls for both the groups was done. The age group of premenopausal hypertensive women was 30-50 years and for postmenopausal hypertensive women it was 50-70 years. Atenolol (10-40 mg/day) was prescribed to half of the patients from both the study groups and the other half was prescribed Enalapril (5-20mg/day). The assessment of trace elements was done during the follow up before and after 3, 6, 12 months of treatment. Results: Effectiveness of both the drugs, Atenolol and Enalapril were found equal in deceasing blood pressure. A significant increase in the serum level of lead (P<0.05), significant decrease in the level of Magnesium (P<0.05), non-significant increase in the level of zinc and no change in the level of Vanadium and aluminum was observed in newly diagnosed pre-and postmenopausal women with essential hypertension as compared to normal control. Conclusions: There is association of high level of blood lead and low level of magnesium to essential hypertension in pre and postmenopausal women without any renal disease. High plasma vanadium levels were not found in hypertensives with normal renal functions with respect to control.
2. Ekamekci OB, Donma O, Tunckale A. Angiotensin converting enzyme and metals is untreated esssential hypertension. Biol Trac Elem Res 2003; 95(3) :203-10.
3. Saito N. Overview suppression effect of essential trace elements on arteriosclerotic development and its mechanism. Nippon Rinsho 1996; 54(1): 106-10.
4. Vivoli G, Bergomi M, Rovesti S et al. Zinc, copper or zinc or copper dpendent enzymes in human hypertension. Biol Trac Elem Res1995: 49 (2-3): 97-106.
5. Karppanen H. Minerlas and blood pressure. Ann med 2001; 23(3): 299-305.
6. Purvis JR and Movahed A. Magnesium disorders and cardiovascular disease. Clin Cardiol 1992; 15: 556-568.
7. Altura BM, Altura BT. New prospectives on the role of magnesium in the pathophysiology of cardiovascular system. J Clinical Aspects Magnesium 1985; 4: 226-244.
8. Altura BM, Zhang A, Altura BT. Magnesium, hypersensitive vascular diseases, atherogenesis, subcellular compartmentation of Calcium and Magnesium and vascular contractility. Minor Electrolyte Metabol 1993; 19: 323-326.
9. Motoyama T, Sano H, Fukuzaki H. Oral magnesium supplementation in patients with essential hypertension. Hypertension 1999; 1: 227-322.
10. Prasad AS. Zinc: the biology and therapeutics of an ion. Ann Int Med 1996; 125: 142-143.
11. Saltman P. Trace elements and blood pressure. Ann Int Med 1993; 98: 823-827.
12. Gonick HC, Behari JR. Is lead exposure is the principle cause of essential hypertension? Med Hypothesis 2002; 59(3): 239-46.
13. Pirkle JI, Schwartz J, Landis JR et al. The relationship between blood lead levels and blood pressurre and its cardiovascular risk complications. Am J Epidemiol 1985; 121: 246-248.
14. Gonick HC, Ding Y, Bondy SC et al. Lead induced hypertension: interplay of nitric oxide and reactive oxygen species. Hypertension 1997; 30: 1487-1492.
15. Lin JL, Lim PS. Does lead play a role in the development of renal insufficiency in some patients with essential hypertension. J Huro Hypertens 1994; 8: 495-500.
16. Navarro JA, Grandillo VA, Salgedo O. Vanadium and aluminum levels in chronic renal insufficiency. Zxareb 1991; 29-8-29-9.
17. Peckzkowska M. Influence of angiotensin I converting enzyme inhibitors on selected parameters of zinc metabolism. Pol Arch Med Wewn 1996; 1: 32-8.
18. Rubio-Leungo MA, Maldonade- Martin A, Gill-Extrema et al. Variagtion in magensium and zinc un hypertensive patients recieving different treatments. Am J Hypertens 1995; 8(7): 689-95.
19. Christopher B, Scott MS, John J Et al. Effects of atenelol versus enalapril on cardiovascuar fitness and serum lipids in physically active hypertensive patients. Am J Cardiol 1997; 79: 1065-1069.
20. Victor A, Grandillo, Jorge E, Tahan, Octavia Salgado et al. The influence of the blood level of lead, aluminum and vanadium upon the arterial hypertension. Clinical Chemica Acta 1995; 233: 47-59.
21. O'Connor DT, SgtrauseL, Saltman P et al. Serum zinc is unaffected by effective captopril treatment of hypertension. J Clins hypertens 1987; 3: 405-408.
22. Golik A, Modai D, Averbul et al. Zinc metabolism in patients treated with captopril versus enalapril. Metabolism 1990; 39: 665-667.
23. Calero M, Sampalo A, Freire J. Variquones de renina y aldosterone en enformos hipertenos. Ann Med Interna 1998; 5: 227-231.
24. Prasad AS. Zinc and enzymes. In Prasad AS (ed) Biochemistry of Zinc, New York, Plenum Press, 1993, pp 17-53.
25. Ronit Zaidenstein, Victor Dishi, Alexander Blatt et al. Effects of captopril and enalapril on zinc metabolism in hypertensive patients. J American College of Nutrition, 1988; 17 (1): 75-78.
26. Resnick LM,Gupta RK, Laragh JH. Intracellular free magnesium in erythrocytes of essential hypertension. Proc Natl Acad Sci 1994; 81: 6511-6515.
27. Altura DM, Zhang A, Altura BT. Magnesium hypertensive vascular disease, atherogenesis, subcellular compartmenttion of Calcium and Magnesium and vascular contractility. Miner Electrolyte Metabol 1993; 19: 323-326.
28. Altura BM, Altura BT, Carella A. Mg-Ca interaction in ccontraction of vascular smooth muscle. Can J Physiol Pharmacol 1987; 65: 729-745.
29. Cocco G, Iselin HU, Strozzi et al. Magnesium depletion in patients on long term chlorothalidone therpay of essential hypertension. Eur J Clin Pharmacol 1987; 32: 335-338.
30. Miroslav Simunic, Zvonko Rumboldt, Dragon Ljutic et al. Ramipril decreased chlorthalidone-induced loss of nagnesium and potassium in hypertensive patients. J Clin Pharmacol1995; 35: 1150-1155.
31. M Angustias Rublo, Leungo, Antonia, Maldonado-Martin, Blas et al. Variations in magnesium and zinc in hypertensive patients recieving different treatments. American Journal of Hypertensiion 1995; 8: 689-695.
32. Motoyama T, Sano H, Fukuzata A. Oral magnesium supplementation in patient with essential hypertension. Hypertension 1989; 13: 227-232.
33. Whyte KF, Addis GJ, Whitesmith R. Adrenorecptor control of plasma magnesium in man. Am J Hypertens 1993; 6: 41 - 5.
34. Ritz E, Wiecek A, Stoeppier et al. Role of lead in hypertension and renal failure. Trace Elem Med 1986; 3 : 34-46.
35. Altura BM, Altura BT, Carella A. Mg-Ca interaction in ccontraction of vascular smooth muscle. Can J Physiol Pharmacol 1987; 65: 729-745.
36. Saito N. Overview suppression effect of essential trace elements on arteriosclerotic development and its mechanism. Nippon Rinsho 1996; 54(1): 106-10.
Copyright (c) 2016 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.